Search Share Prices
ReNeuron lands £1.5m grant to develop retinal disease treatment
Clinical stage stem cell business ReNeuron Group has won a £1.5m grant to advance development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina.
The grant, from innovation agency Innovate UK, will help to fund a collaborative programme between ReNeuron and its partners the Cell & Gene Therapy Catapult, Roslin Cell Therapies and University College London.
Sharon Grimster, Welsh General Manager at ReNeuron Group, said: "We and our collaborators are delighted to have won this latest grant from Innovate UK to develop a suite of robust and reliable release and characterisation assays reflecting the mechanism of action of our hRPC cell therapy candidate."
The hRPC cell therapy candidate is currently in the midst of phase I/II trials in the United States, studying the effects of the treatment on patients with genetic disorder retinitis pigmentosa.
The development of the treatment was earlier funded by Innovate UK, who supported the late pre-clinical development of the cell therapy candidate.
"This is a challenging but vital part of the broader commercial manufacturing strategy for the therapy and we are pleased to be working with leading academic and commercial manufacturing partners on this important programme of work," said Grimster.
As of 0822 BST, ReNeuron Group's shares were up 4.96% at 74.00p.